References

About Arthritis, http://www.depuyorthopaedics.com


Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion. Chronic disease – press room. Atlanta, GA.


http://www.merck.com/mmhe/print/sec03/ch033/ch033c.html, Heart attack.


Iowa Prostate Cancer Consensus Recommendations Committee. The Iowa prostate cancer consensus: Screening and management in men aged 75 years of age and older.


References


Schiel, R., Ulbrich, S., Muller, U.A. (1998). Quality of diabetes care, diabetes knowledge and risk of severe hypoglycaemia one and four years...


cognitive ability are associated with prescribed medications in old age.
Int J Ger Psychiatry, 19, 327-332.
for nursing home physicians and staff to reduce use of non-steroidal
anti-inflammatory drugs among nursing home residents. Med Care, 39
Stenager, E.N., Stenager, E. and Jensen, K. (1994). Attempted suicide,
depression and physical diseases: a 1-year follow-up study.
Psychotherapy Psychosom, 61 (1-2), 65-73.
Stern, R.A., Davis, J.D., Rogers, B.L., et al. (2004). Preliminary study of
the relationship between thyroid status and cognitive and neuropsy-
chiatric functioning in euthyroid patients with Alzheimer dementia.
Cognitive Behav Neuro, 17, 219-223.
Stern, Y., Hlabeck, C., Moeller, J., et al. (2005). Brain networks associ-
ated with cognitive reserve in healthy young and old adults. Cerebral
Cortex, 15, 394-402.
Stevenson, J.S. (2005). Alcohol use, misuse, abuse and dependence in
Strandberg, T.E., Strandberg, A., Rantanen, K., et al. (2004). Low choles-
terol, mortality and quality of life in old age during a 39-year follow-
up. J Amer Coll Cardiol, 44: 1002-1008.
Strawbridge, W.J., Deleger, S., Roberts, R.E., et al. (2002). Physical activ-
ity reduces the risk of subsequent depression for older adults. Amer
J Epi, 156 (4), 328-334.
risk factors for falls in older people with lower limb arthritis.
depression in chronic low back pain: review and recommendations.
Pain, 50, 5-13.
and mortality in men and women in the EPIC-Norfolk United Kingdom
prospective cohort study, Amer J Epidemiol, 158, 1202-1209.
Care, 12 (5): 248.
patients attending a community clinic in Hong Kong. Patient Educ
Couns, 36 (3): 259-70.
References


Ware, J.E., Jr., Bayliss, M.S., Rogers, W.H., et al. (1996). Differences in 4-year health outcomes for elderly and poor, chronically ill patients treated in HMO and fee-for-service systems. Results from the Medical Outcomes Study. JAMA, 276 (13): 1039-47.


White House Conference on Aging (2005), San Diego, CA.


About the Authors

Dr. Stephen J. Morewitz is President of the consulting firm, STEPHEN J. MOREWITZ, Ph.D., & ASSOCIATES, Buffalo Grove, IL and San Francisco and Tarzana, CA, which was founded in 1988. He is Adjunct Professor and Past Research Dean at the California School of Podiatric Medicine at Samuel Merritt College, Oakland, CA, and a Lecturer in the Graduate Health Care Administration Program, Department of Public Affairs and Administration, California State University, East Bay. He has been on the faculty or staffs of Michael Reese Hospital, University of Illinois at Chicago, College of Medicine and School of Public Health, DePaul University, and Argonne National Laboratory, Division of Biological and Medical Research. Dr. Morewitz is the author of more than 80 publications, including Chronic Diseases and Health Care: New Trends in Diabetes, Arthritis, Fibromyalgia, Osteoporosis, Back Pain, Cardiovascular Disease and Cancer (New York: Springer, 2006) and the award-winning book, Domestic Violence and Maternal and Child Health (New York: Springer, 2004).

Dr. Mark L. Goldstein, Ph.D., is a licensed clinical psychologist in Illinois. Dr. Goldstein has a private practice specializing in forensic psychology and counseling. He is also an adjunct professor at the Chicago School of Professional Psychology and consultant to a suburban school system. Dr. Goldstein received his Ph.D. from the University of Florida and was previously a core faculty member at the Illinois School of Professional Psychology and adjunct professor at the University of Illinois College of Medicine and Roosevelt University. He is the editor of a book, Innovations in Behavioral Science Education, and the author of numerous professional articles.
Author Index

Adams, A.S., 87-88
Ades, P.A., 129, 136-137
Aggarwal, A., 136
Ai, A.L., 132
Al Snih, S., 71
Aldwin, C.M., 30-31
Allaire, S., 100
Allen, R., 51
Amoako, E.P., 17-20
Anderson, R.J., 36, 38, 69
Andrews, J.O., 12
Anstey, K.J., 44, 46
Araki, A., 75, 79, 86
Arden, N., 101
Arnold, L.M., 96
Aronow, W.S., 64
Artinian, N.T., 137-138
Audisio, R.A., 141, 147, 149-152
Auerbach, A.D., 130
Backman, L., 41
Balducci, L., 141-142
Barnett, A., 27
Barzilay, J.I., 60-61
Bastida, E., 62, 66
Bell, D.S., 79-80
Bell, R.A., 60, 69-70, 73, 87
Berg, B., 41
Berger, J.S., 127
Berkman, B., 126, 132
Berman-Evans, B., 20
Bernard, D.M., 23
Bernardi, D., 141
Bertagnoli, R., 120
Bertera, E.M., 76, 86
Beswick, A.D., 135, 137
Biessels, G.J., 69
Birge, S.J., 6, 94
Birren, J.E., 44
Black, S.A., 61, 70
Blackman, L., 48
Blaum, C.S., 58
Blazer, D.G., 31, 35
Boccia, A., 150
Boer, K., 147-148
Bookwala, J., 102
Boonen, S., 103
Boorman, P., 150
Bopp, K.L., 49
Borbasi, S., 133
Bowling, A., 28
Braun, A., 87-88
Braver, T.S., 46
Brenes, G.A., 39
Bressler, H.B., 8-9
Brillantes, A.M., 56
Brokalaki, E.I., 157
Brown, A.F., 61
Brown, D.L., 127
Brown, J.S., 66
Brown, S.C., 101
Brownie, S., 122
Bruce, D.G., 71, 73
Bruckner, M., 84
Bucks, R.S., 53
210  Author Index

Bufalari, A., 149
Burge, M.R., 59, 63, 77, 82
Burge, R.T., 24
Burnight, K.P., 49
Butler, J., 125
Butler, R. N., 44
Byrne, M.D., 48
Caja, S.J., 46
Calvo-Alen, J., 100
Caporali, R., 93
Carey, T.S., 9
Carney, C., 70
Carr, L., 6
Caruso, L.B., 70, 72-73
Caspi, A., 41
Castel, A.D., 48
Cerella, J., 45
Chalfonte, B.L., 48
Chan, C.W., 146
Chasens, E.R., 62, 75
Chelliah, A., 59, 63, 77, 82
Chen, H., 143
Chi, I., 71
Chockalingam, A., 10
Chou, K.L., 71
Christensen, H., 46
Chu, L.W., 126
Churchill, L.R., 16
Cijevschi, C., 95
Cimmino, M.A., 102
Clark, F., 111
Clark, N.M., 137, 139
Clarkson-Smith, L., 45
Cohen, M., 126
Cohen, S., 32
Cole, C.S., 53
Colleau, S., 142, 145
Comijs, H.C., 50
Cooper, C., 102
Costa, P.T., 41
Craik, F.I.M., 48
Crofford, L.J., 117-118
Crogan, N., 30

Cronan, T.A., 7, 104
Crooks, V.C., 58, 60, 87
Crowther, M., 29
Curry, L.C., 18-20
Dajczman, E., 151
Daly, D.D., 6
Daly, R.M., 113
D’Astolfo, C.J., 8-9, 96, 98, 105
Daviglus, M.L., 29
Dawson-Hughes, B., 6, 94, 101
De Berardis, G., 65, 84, 86
De Beurs, E., 39
De Graaf, E.J., 150
De Groot, M., 38
De Leo, D., 38
De Mendonca, A., 53
De Nicola, L., 85
Del Aguila, M.A., 84
Del Rincon, I., 91
Den Heijer, T., 69
Dennis, N.A., 51-52
Delvecchio, W.F., 41
De Rekeneire, N., 57
Di Maio, M., 144
Dionne, C.E., 8-9
Dixon, R.A., 48
Dodge, J.A., 137
Doolan, D.M., 12
Doran, M.F., 91
Dracup, K.A., 132
Dreicer, R., 153
Drungle, S.C., 87
Dumont, C.J., 134
Duverne, S., 49
Dye, C.J., 88
Dykes, P.C., 140

Eason, S.L., 64
Edelson, E., 26
Egberts, E.H., 59
Ehrlich, G.E., 8
Elhendy, A., 1
Ellison, C.E., 33
Author Index

Elman, C.S., 133
Emanuel, E.J., 39
Emery, P., 109
Eng, J., 155
Engle, V.F., 120
Epstein, S., 114
Extermann, M., 141-142

Fabiani, M., 49
Farias, S.T., 53
Fattorolli, F., 135
Feldstein, A., 116-117
Felson, D.T., 101
Felton, B.J., 75
Ferrans, C.E., 159
Ferrer-Caja, E., 46
Ferrara, N., 135
Fick, D.M., 17-18
Ficorella, C., 149
Fishbain, D.A., 38
Fisher, B.J., 38
Fisher, D.L., 46
Fleischman, D.A., 53
Focht, B.C., 101
Fontaine, K.R., 124
Forjuoh, S.N., 21
Fox, P.L., 9
Fox, S.A., 160
Franck, W.M., 6, 92, 102
Franklin, S.S., 125
Friedlander, M.A., 63
Friedman, H.S., 41
Froehner, M., 155
Frölicher, E.S., 12
Fu, M.R., 158

Gabbay, R.A., 74, 81
Gabriel, S., 28, 91-93
Gabrieli, J.D., 53
Gage, B.F., 94-95
Gagli, J.L., 67-68, 86
Ganz, D.A., 111
Ganz, P.A., 145
Gary, R., 137-138

Gass, M., 6, 94, 101
Gavard, J.A., 38
Genovese, M.C., 108
Giangregorio, L., 116
Gilden, J.L., 89
Gilmer, D.F., 50
Giltay, E.J., 32
Given, B., 143, 146
Glaser, R.A., 46
Glassman, A., 37
Golby, A., 53
Goldenberg, D.L., 117
Gonzalez, G.R., 38
Gonzalez, B., 138
Gonzalez, E.B., 7
Gonzalez, Q.H., 150
Gonzalez-Gay, M.A., 108
Gott, M., 131
Goulding, M.R., 17-18, 20
Gowin, K.M., 7, 96
Goya Wannamethee, S., 72-73
Grady, C.I., 52
Graybiel, A.M., 44
Grazio, S., 94
Gridelli, C., 152-153
Greene, D.A., 67
Griffin, K.W., 106
Griffin, M.R., 17, 19-21, 109-110
Gu, X., 15
Gustafsson, T.M., 57
Guyton, A.C., 31

Haaz, S., 124
Hadjistavropoulos, H.D., 39
Hall, J.E., 31
Hallberg, I.R., 101
Han, S.Y., 75
Hansberry, M.R., 62
Hartley, A.A., 45
Hartvigsen, J., 8, 99
Hasserius, R., 6-7, 102
Hasslacher, C., 59, 63
Hedden, T., 53
Heer, T., 127
<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heisler, M.</td>
<td>89</td>
</tr>
<tr>
<td>Helfand, A.E.</td>
<td>83-84</td>
</tr>
<tr>
<td>Helmes, E.</td>
<td>51</td>
</tr>
<tr>
<td>Helson, R.</td>
<td>41</td>
</tr>
<tr>
<td>Helmick, C.G.</td>
<td>99</td>
</tr>
<tr>
<td>Henry, J.D.</td>
<td>50</td>
</tr>
<tr>
<td>Heriot, A.G.</td>
<td>148</td>
</tr>
<tr>
<td>Herpertz, S.</td>
<td>73-74</td>
</tr>
<tr>
<td>Herrlinger, C.</td>
<td>20</td>
</tr>
<tr>
<td>Hiatt, W.R.</td>
<td>64</td>
</tr>
<tr>
<td>Higginbotham, N.H.</td>
<td>9, 120</td>
</tr>
<tr>
<td>Ho, P.</td>
<td>150</td>
</tr>
<tr>
<td>Hochberg, M.C.</td>
<td>109-111, 122-123</td>
</tr>
<tr>
<td>Hogan, P.</td>
<td>22</td>
</tr>
<tr>
<td>Holland, N.W.</td>
<td>7</td>
</tr>
<tr>
<td>Hollander, P.</td>
<td>83-84</td>
</tr>
<tr>
<td>Holman, H.</td>
<td>110, 123</td>
</tr>
<tr>
<td>Holstein, A.</td>
<td>59</td>
</tr>
<tr>
<td>Honecker, F.</td>
<td>150-151</td>
</tr>
<tr>
<td>Hootman, J.M.</td>
<td>99</td>
</tr>
<tr>
<td>Hornick, T.R.</td>
<td>21</td>
</tr>
<tr>
<td>Houldin, A.D.</td>
<td>145</td>
</tr>
<tr>
<td>Hricik, D.E.</td>
<td>63</td>
</tr>
<tr>
<td>Hu, W.Y.</td>
<td>157-158</td>
</tr>
<tr>
<td>Huh, H.T.</td>
<td>52</td>
</tr>
<tr>
<td>Humphreys, B.K.</td>
<td>8-9, 96, 98, 105</td>
</tr>
<tr>
<td>Hybels, C.F.</td>
<td>35</td>
</tr>
<tr>
<td>Iki, M.</td>
<td>94</td>
</tr>
<tr>
<td>Ishida, Y.</td>
<td>103</td>
</tr>
<tr>
<td>Ishiguro, T.</td>
<td>80</td>
</tr>
<tr>
<td>Ismail, A.A.</td>
<td>6</td>
</tr>
<tr>
<td>Issa, S.N.</td>
<td>92-93, 101-102</td>
</tr>
<tr>
<td>Iwamoto, J.</td>
<td>114</td>
</tr>
<tr>
<td>Jaarsma, T.</td>
<td>139</td>
</tr>
<tr>
<td>Jack, L.</td>
<td>79, 81</td>
</tr>
<tr>
<td>Jackson, J.L.</td>
<td>134</td>
</tr>
<tr>
<td>Jacobs, J.M.</td>
<td>8, 99, 104</td>
</tr>
<tr>
<td>Jacoby, L.L.</td>
<td>48</td>
</tr>
<tr>
<td>Jaklitsch, M.T.</td>
<td>143, 151</td>
</tr>
<tr>
<td>Jakobsson, U.</td>
<td>101</td>
</tr>
<tr>
<td>Jandorf, L.</td>
<td>160</td>
</tr>
<tr>
<td>Jang, Y.</td>
<td>37</td>
</tr>
<tr>
<td>Janssen, I.</td>
<td>93</td>
</tr>
<tr>
<td>Jette, A.M.</td>
<td>31</td>
</tr>
<tr>
<td>Jiang, S.L.</td>
<td>126</td>
</tr>
<tr>
<td>Johnson, J.E.</td>
<td>40</td>
</tr>
<tr>
<td>Johnson, M.K.</td>
<td>48</td>
</tr>
<tr>
<td>Johnson, N.J.</td>
<td>32</td>
</tr>
<tr>
<td>Jones, C.J.</td>
<td>41</td>
</tr>
<tr>
<td>Juarez, L.</td>
<td>90, 99</td>
</tr>
<tr>
<td>Kagay, C.R.</td>
<td>160</td>
</tr>
<tr>
<td>Kahn, R.L.</td>
<td>29</td>
</tr>
<tr>
<td>Kanaya, A.M.</td>
<td>8, 87</td>
</tr>
<tr>
<td>Kapiteijn, E.</td>
<td>149</td>
</tr>
<tr>
<td>Kapp, M.B.</td>
<td>16</td>
</tr>
<tr>
<td>Kaski, J.C.</td>
<td>134</td>
</tr>
<tr>
<td>Katon, W.</td>
<td>81</td>
</tr>
<tr>
<td>Katz, J.N.</td>
<td>22, 24</td>
</tr>
<tr>
<td>Kaufman, S.R.</td>
<td>16</td>
</tr>
<tr>
<td>Kawachi, I.</td>
<td>31</td>
</tr>
<tr>
<td>Keen, R.W.</td>
<td>24</td>
</tr>
<tr>
<td>Keller, H.H.</td>
<td>30</td>
</tr>
<tr>
<td>Kemper, S.</td>
<td>49</td>
</tr>
<tr>
<td>Kennedy, M.</td>
<td>64</td>
</tr>
<tr>
<td>Keysor, J.J.</td>
<td>31</td>
</tr>
<tr>
<td>Kiecolt-Glaser, J.R.</td>
<td>32</td>
</tr>
<tr>
<td>Kimble, L.P.</td>
<td>137</td>
</tr>
<tr>
<td>Kisley, M.A.</td>
<td>51-52</td>
</tr>
<tr>
<td>Kloner, R.A.</td>
<td>60, 65</td>
</tr>
<tr>
<td>Klotz, U.</td>
<td>20</td>
</tr>
<tr>
<td>Knowler, W.C.</td>
<td>30</td>
</tr>
<tr>
<td>Koenig, H.G.</td>
<td>32, 128, 132</td>
</tr>
<tr>
<td>Kohout, M.L.</td>
<td>32</td>
</tr>
<tr>
<td>Koizumi, K.</td>
<td>152</td>
</tr>
<tr>
<td>Kolh, P.</td>
<td>21</td>
</tr>
<tr>
<td>Koperna, T.</td>
<td>149</td>
</tr>
<tr>
<td>Kornblith, A.B.</td>
<td>144-145</td>
</tr>
<tr>
<td>Kosiborod, M.</td>
<td>10</td>
</tr>
<tr>
<td>Kozanoglu, E.</td>
<td>95-96</td>
</tr>
<tr>
<td>Krantz, N.</td>
<td>31</td>
</tr>
<tr>
<td>Krause, N.</td>
<td>33</td>
</tr>
<tr>
<td>Krishnan, M.</td>
<td>63, 91-92</td>
</tr>
<tr>
<td>Kristofferson, M.L.</td>
<td>132</td>
</tr>
<tr>
<td>Kroot, E.J.</td>
<td>91</td>
</tr>
<tr>
<td>Kubzansky, L.D.</td>
<td>32</td>
</tr>
<tr>
<td>Author</td>
<td>Pages</td>
</tr>
<tr>
<td>-------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Kunik, C.L.</td>
<td>137</td>
</tr>
<tr>
<td>Kurtz, M.E.</td>
<td>144-145</td>
</tr>
<tr>
<td>Kyllonen, P.C.</td>
<td>49</td>
</tr>
<tr>
<td>LaBerge, D.</td>
<td>45</td>
</tr>
<tr>
<td>Lacey, E.A.</td>
<td>138</td>
</tr>
<tr>
<td>Langer, C.J.</td>
<td>151-153</td>
</tr>
<tr>
<td>Latkauskas, T.</td>
<td>148-149</td>
</tr>
<tr>
<td>Lawton, M.P.</td>
<td>29</td>
</tr>
<tr>
<td>Lebow, J.</td>
<td>28</td>
</tr>
<tr>
<td>Le Parc, J.M.</td>
<td>93</td>
</tr>
<tr>
<td>Lehto, U.S.</td>
<td>145</td>
</tr>
<tr>
<td>Lerman, I.G.</td>
<td>58, 60</td>
</tr>
<tr>
<td>Lesperance, M.E.</td>
<td>140</td>
</tr>
<tr>
<td>Lev, E.L.</td>
<td>159</td>
</tr>
<tr>
<td>Leveille, S.G.</td>
<td>104</td>
</tr>
<tr>
<td>Levinson, M.R.</td>
<td>40</td>
</tr>
<tr>
<td>Li, J.</td>
<td>48</td>
</tr>
<tr>
<td>Li, S.C.</td>
<td>48</td>
</tr>
<tr>
<td>Liang, W.</td>
<td>156-157</td>
</tr>
<tr>
<td>Licht-Strunk, E.</td>
<td>38</td>
</tr>
<tr>
<td>Lien, M.C.</td>
<td>51</td>
</tr>
<tr>
<td>Light, L.L.</td>
<td>48</td>
</tr>
<tr>
<td>Liu, S.</td>
<td>78</td>
</tr>
<tr>
<td>Lock, K.</td>
<td>13</td>
</tr>
<tr>
<td>Logminiene, Z.</td>
<td>22</td>
</tr>
<tr>
<td>Lorig, K.</td>
<td>110, 123</td>
</tr>
<tr>
<td>Louis, E.D.</td>
<td>53</td>
</tr>
<tr>
<td>Low, L.F.</td>
<td>44</td>
</tr>
<tr>
<td>Lovheim, H.</td>
<td>120</td>
</tr>
<tr>
<td>Luchsinger, J.A.</td>
<td>69</td>
</tr>
<tr>
<td>Lynn, S.</td>
<td>85</td>
</tr>
<tr>
<td>Macfarlane, G.J.</td>
<td>39</td>
</tr>
<tr>
<td>Machado, G.M.</td>
<td>100</td>
</tr>
<tr>
<td>Mackinnon, A.</td>
<td>51</td>
</tr>
<tr>
<td>Mackowiak-Cordoliani, M.A.</td>
<td>53</td>
</tr>
<tr>
<td>Magai, C.</td>
<td>28</td>
</tr>
<tr>
<td>Magni, G.</td>
<td>39</td>
</tr>
<tr>
<td>Maly, R.C.</td>
<td>144, 146, 156-157</td>
</tr>
<tr>
<td>Manini, T.M.</td>
<td>13</td>
</tr>
<tr>
<td>Manton, K.G.</td>
<td>15</td>
</tr>
<tr>
<td>Maradit-Kremers, H.</td>
<td>91-92</td>
</tr>
<tr>
<td>Maraldi, C.</td>
<td>13</td>
</tr>
<tr>
<td>Maravic, M.</td>
<td>6, 24</td>
</tr>
<tr>
<td>March, L.M.</td>
<td>101</td>
</tr>
<tr>
<td>Marchionni, N.</td>
<td>129, 136</td>
</tr>
<tr>
<td>Marin, R.</td>
<td>63</td>
</tr>
<tr>
<td>Mark, A.E.</td>
<td>93</td>
</tr>
<tr>
<td>Mark, R.E.</td>
<td>48</td>
</tr>
<tr>
<td>Marso, S.P.</td>
<td>64</td>
</tr>
<tr>
<td>Masoudi, F.A.</td>
<td>131</td>
</tr>
<tr>
<td>Matasar, M.J.</td>
<td>143, 149-151</td>
</tr>
<tr>
<td>Matsuoka, K.</td>
<td>86</td>
</tr>
<tr>
<td>Mattay, V.S.</td>
<td>49</td>
</tr>
<tr>
<td>Maurits, N.M.</td>
<td>52</td>
</tr>
<tr>
<td>Maynard, C.</td>
<td>127</td>
</tr>
<tr>
<td>Mazari, C.</td>
<td>37</td>
</tr>
<tr>
<td>Masoudi, F.A.</td>
<td>26</td>
</tr>
<tr>
<td>McCauley, J.W.</td>
<td>118</td>
</tr>
<tr>
<td>Mccerney, M.K.</td>
<td>31</td>
</tr>
<tr>
<td>McClean, W.J.</td>
<td>9, 120</td>
</tr>
<tr>
<td>McClung, M.R.</td>
<td>115</td>
</tr>
<tr>
<td>McCoy, C.B.</td>
<td>160</td>
</tr>
<tr>
<td>McCrae, R.R.</td>
<td>41</td>
</tr>
<tr>
<td>McDougall, G.J.</td>
<td>47</td>
</tr>
<tr>
<td>McDowell, J.</td>
<td>74</td>
</tr>
<tr>
<td>McGuire, L.C.</td>
<td>51</td>
</tr>
<tr>
<td>McLean, L.</td>
<td>31</td>
</tr>
<tr>
<td>McFadden, S.</td>
<td>28</td>
</tr>
<tr>
<td>McPhillips, J.B.</td>
<td>60</td>
</tr>
<tr>
<td>Mehnert, A.</td>
<td>144</td>
</tr>
<tr>
<td>Mell, T.</td>
<td>51</td>
</tr>
<tr>
<td>Meller, S.</td>
<td>133</td>
</tr>
<tr>
<td>Mellick, E.</td>
<td>38</td>
</tr>
<tr>
<td>Mellstrom, D.</td>
<td>94</td>
</tr>
<tr>
<td>Menec, V.H.</td>
<td>30</td>
</tr>
<tr>
<td>Messana, J.M.</td>
<td>63</td>
</tr>
<tr>
<td>Miazgowski, T.</td>
<td>6, 94</td>
</tr>
<tr>
<td>Micik, S.</td>
<td>133</td>
</tr>
<tr>
<td>Mikuls, T.</td>
<td>100</td>
</tr>
<tr>
<td>Miller, H.S.</td>
<td>132-133</td>
</tr>
<tr>
<td>Mitchell, J.L.</td>
<td>157-158</td>
</tr>
<tr>
<td>Mitchell, K.J.</td>
<td>48</td>
</tr>
<tr>
<td>Monane, M.</td>
<td>17, 20</td>
</tr>
<tr>
<td>Moore, R.</td>
<td>134</td>
</tr>
<tr>
<td>Moos, R.H.</td>
<td>40</td>
</tr>
<tr>
<td>Morewitz, S.</td>
<td>1, 130, 132, 138</td>
</tr>
</tbody>
</table>
Murase, Y., 67
Muss, H.B., 146-148
Naghavi, M., 26
Narendran, V., 61
Narita, M., 35
Naveh-Benjamin, M., 48
Nevitt, M.C., 101
Newton, J.L., 66, 103
Nicolucci, A., 83

Oberauer, K., 49
Olszowska, A., 64
O’Malley, N.C., 16
O’Neill, T.W., 102
Onishi, J., 36
Orstavik, R.E., 100
Oshida, Y., 80
Ostir, G.V., 72
Otiniano, M.E., 57-58, 60-62, 65, 72
Ottenbacher, K.J., 60, 67

Pande, I., 103
Paquet, M., 135
Pargament, K.I., 32
Park, C.L., 32
Parker, P.A., 145
Pasvogel, A., 30
Patankar, S.K., 150
Patel, U.D., 64, 85
Pease, C.T., 100
Pedro, L.W., 144
Pei, C.K., 126
Penning-van Beest, F.J., 121
Penninx, B.W., 76, 105-106, 132-133, 145-146
Penttinen, J., 38
Perrone, F., 144
Pescatello, L.S., 79
Peterson, C., 32
Pfister, A.K., 115
Philbin, E.F., 130
Phillips, L.H., 51
Piette, J.D., 89
Pluchon, C., 51
Polanczyk, C.A., 134
Prince, M., 36
Prince, R.L., 113
Prins, N.D., 54
Proietti, F.A., 96
Puggaard, L., 31
Qiu, C., 128-129
Rabbit, P.M., 46
Radford, S.A., 53
Ragland, D.R., 37
Raji, M.A., 60, 68, 87
Ramesh, H.S., 141-142
Ranchor, A.V., 145
Rankin, K.P., 53
Ratcliff, R., 46
Rathore, S.S., 127
Raz, N., 48
Redaelli, A., 27
Renner, V.J., 44
Repetto, L., 141-143
Retchin, S.M., 16
Reuter-Lorenz, P.A., 49
Revenson, T.A., 75
Rhee, M.K., 87-88
Ribeiro, L.S., 96
Rich, M.W., 128, 134
Riegel, B.J., 132
Robbins, A.S., 66
Roberts, B.W., 41
Robinson, J.D., 145
Robinson, R.L., 24
Robison, J., 37
Roche, R.J., 141, 143
Rodriguez, K.L., 16
Roman, M.J., 91-92
Romanelli, J., 130, 132-133
Roscoe, L.A., 39
Rosenstock, J., 57, 77-78, 81-82
Rossi, A., 142
Roumie, C.L., 17, 19-21
Author Index

Tsuji, T., 99
Tun, P.A., 68, 70, 72
Turner, J., 145

Ubel, P.A., 16
Ueda, T., 66
Unutzer, J., 37

Vailas, L.I., 30
Valentijn, S.A., 52
Valmadrid, C.T., 62
Van de Velde, C.J., 149-150
Van Gool, C.H., 36
Verbrugge, L.M., 90, 99
Verhaeghen, P., 48
Vinik, A.I., 67
Vitaliano, P.P., 32
Volk, R.J., 153, 159
Volpato, S., 13
Von Goeler, D.S., 87
Von Moltke, L.L., 20

Wachtel, M.S., 58
Wanebo, H.J., 146
Ware, J.E., 17
Wasserbauer, N., 145
Weaver Cargin, J., 47
Webb, R., 104
Wen, L.K., 75-76, 89

Wengstrom, Y., 158
West, C., 74
Weycker, D., 107
Wheeler, J.R., 139
White, J.V., 78-80
White, K.P., 7, 95
Wiggins, R.D., 28
Wilkins, C.H., 6, 94
Williams, J.W., 69, 73, 81
Williams, R.B., 31
Williams, S.A., 158-159
Wilson, R.S., 31, 35, 41
Wirth, M.P., 155
Wittmann, W., 59, 63
Wolfe, F., 7, 104
Wolff, J.L., 1
Worthington, E.L., 33
Wray, L.A., 70-71
Wright, J.G., 111

Yamamoto, H., 50
Yang, Y., 36
Yepes-Rios, M., 160
Young, A.J., 16

Zacks, R.T., 48
Zareba, G., 118
Zeyfang, A., 86
Zelinski, E.M., 49
Subject Index

Abatacept, 108–9
ACE inhibitors, 59
Acetaminophen, 109, 110
Activities of daily living (ADLs), 2
cancer and, 143
diabetes and, 71
low back pain and, 99, 104
osteoarthritis and, 111
prostate cancer and, 154–55
Acupuncture, 120
Acute metabolic emergencies, 67–68
Acute myocardial infarction (AMI), 17, 126–28, 135.
See also Myocardial infarction
coping with, 133
disability and quality of life, 129, 130
patient education on, 139
rheumatoid arthritis and, 91, 92
Adalimumab (Humira), 108
Adhedonia, 36
Aerobic exercise, 31, 79, 80, 86, 119
African-Americans
arthritis in, 4, 124
breast cancer in, 156
cancer in, 11
cardiovascular disease in, 130
diabetes in, 4, 57, 58, 62, 68, 70, 76, 78, 86, 87
epidemiology of disease in, 2
mammography for, 160
memory impairment in, 47
osteoporosis in, 5, 95
prostate cancer in, 154
Age
cancer and, 11
cardiovascular disease and, 126, 127, 130, 134
fibromyalgia and, 7–8, 104
low back pain and, 8
osteoarthritis and, 92, 93
rheumatoid arthritis and, 91
AIDES (Assessment, Individualization, Documentation, Education, Supervision) method, 20
Air pollution, 14
Alaska Natives, 4, 11
Alcohol-drug interactions, 17, 19, 40
Alcohol use, 13, 39–40, 42–43
acetaminophen and, 109
diabetes and, 73, 79
osteoporosis and, 94, 113, 114
rheumatoid arthritis and, 91
Alendronate, 114, 121, 122
All Wales Research into Elderly Study, 69
Alzheimer's disease (AD), 28, 41, 53
  cardiovascular disease and, 129
  case study of, 55
  diabetes and, 69
  epidemiology of, 2
American College of Rheumatology, 7, 95
AMICA study, 93, 102
Amputations
  diabetes and, 57, 58, 64, 65, 72, 83, 84, 85
  obesity as a risk factor for, 30
Amygdalar atrophy, 69
Amyotrophic lateral sclerosis, 39
Androgen ablation therapy, 154
Aneurysms, 98, 119
Angina, 70, 92, 93, 127, 137
Angioplasty, 127, 134
Ankylosing spondylitis, 25
Anosognosia, 53
Anticholinergic medications, 18
Antidepressants, 18, 117, 118–19
Anxiety, 31, 35, 39, 100, 130, 146
Arthritis, 28. See also
  Inflammatory arthritis;
  Osteoarthritis; Rheumatoid arthritis
  complications and risk factors, 90
  coping with, 105–6
  costs of treating, 23
  diabetes and, 70
  disability and quality of life, 99–100
  epidemiology of, 1, 2, 4
  obesity and, 30
  patient education and self-management, 124
  septic, 101
  social support and, 106
  stress and, 105
Asians, 4, 5, 11
Assisted suicide, 38
Asthma, 1, 14
Astrogliosis, 35
Atherosclerosis, 86, 91, 108
Atrial fibrillation, 94–95, 127–28
Auditory mismatch negativity (MMN), 52
Australian Longitudinal Study of Aging, 46
Autonomic neuropathy, 56
AX Continuous Performance Test, 47
Baby boom generation, 1, 16
Back braces, 119
Back pain (BP), 6, 38. See also
  Low back pain
Balanced Budget Act (1997), 16
Basal ganglia, 44–45
B cells, 109
Beers criteria for inappropriate drug use, 18
Behavioral Risk Factor Surveillance Survey, 124
Benzodiazepines, 18
Beta-adrenergic antagonists, 95
Beta-cryptoxanthin, 106–7
Beta-receptor blockers, 126
Bioconcave vertebral deformities, 6
Birth rate, 1
Bisphosphonates, 114, 115, 117, 121
Blacks. See African-Americans
Blinding deficits, 48
Blindness, 30
Body mass index. See also
  Obesity and overweight
  diabetes and, 70
  osteoarthritis and, 93
  quality of life and, 29, 30
  rheumatoid arthritis and, 91
Bone marrow edema, 93
Cardiovascular functioning, 29–30, 31
Cardiovascular Health Study, 61
Case management services, 15–16, 81
Cataract surgery, 52
Caucasians. See Whites
Centers for Disease Control and Prevention (CDC), 64, 72, 73–74, 80, 84
“Centers for Disease Control and Prevention Data & Trends,” 4
Cerebral small-vessel disease, 54
Cerebrovascular disease, 1, 36, 62, 91
Cervical myelopathy, 91
Cervicocranialgia, 91
CGA. See Comprehensive geriatric assessment
Chemotherapy, 143–44
for breast cancer, 147, 148
for colorectal cancer, 149, 150–51
for lung cancer, 152–53
Childhood adversity, impact of, 35
Chinese patients, 87, 146
Cholesterol levels, 10, 30, 31
Chronic Disease Self-Management Program, 123
Chronic fatigue, 119
Chronic obstructive pulmonary disease, 93
Cirrhosis, 95
Cleveland Clinic, 35, 36
Codeine, 110
Cognitive-behavioral therapy, 117, 118, 159
Cognitive changes, 44–55
case studies of, 54–55
disease effects on, 53–54
learning, 50–52
memory, 47–50
processing speed, 44–47, 54
Cognitive impairment. See also Dementia
arthritis and, 100
cancer and, 141
cardiocvascular disease and, 126, 128, 129
diabetes and, 44, 56, 58, 60, 68–69, 72, 87, 88
diseases associated with, 53–54
fibromyalgia and, 119
inappropriate medication use and, 19
rheumatoid arthritis and, 101
Cognitive reserve, 50
Coherence, EEG, 52
Colorectal cancer, 11, 12
costs of treating, 27
diet and, 13
disability and quality of life, 143
screening for, 160
treatment and rehabilitation outcomes, 148–51
Colorectal Cancer Collaborative Group, 149
Communication problems, 19
Co-morbid conditions
arthritis and, 90
cancer and, 142, 143
diabetes and, 56, 71–72
low back pain and, 9
osteoarthritis and, 93
rheumatoid arthritis and, 91
Complementary and alternative medicine (CAM), 19, 25, 155
Complications
of arthritis, 90
of cancer, 141–42
of cardiovascular disease, 125–29
of diabetes, 57–70
of fibromyalgia, 95–96
of inflammatory arthritis, 93–94
of low back pain, 96–99
of osteoarthritis, 92–93
of osteoporosis, 94–95
of rheumatoid arthritis, 90–92
Comprehensive geriatric assessment (CGA), 141, 142–43, 152
Computerized tomography (CT), 52
Congestive heart failure (CHF), 126, 127, 128–29
diabetes and, 61
disability and quality of life, 130
rheumatoid arthritis and, 91
Conscientiousness, longevity and, 41
Cooperative Cardiovascular Project, 128
Coping
with arthritis, 105–6
with cancer, 145–46
with cardiovascular disease, 131–33
with diabetes, 75
Coronary artery disease (CAD), 64, 130–31
Coronary heart disease (CHD), 10, 125
depression and, 36, 37
diabetes and, 56, 60, 61, 62
rheumatoid arthritis and, 91
Type A personality and, 31
Coronary stent insertion, 21
Co-stimulation modulators, 108
Costs of health care. See Health care costs
C-reactive protein, 13
Creatinine, 20, 63, 85
Cross-Cultural Research on Nutrition in the Older Adult Study Group, 60
Crush vertebral deformities, 6
Dairy products, 78
Death rates. See Mortality rates
Deep-vein thrombosis, 115
Delta-opioid receptor system, 35
Dementia, 28. See also Alzheimer's disease;
Cognitive impairment cardiovascular disease and, 129
diabetics misdiagnosed with, 59
epidemiology of, 2
frontotemporal, 53
low back pain and, 105
osteoporosis and, 103
rheumatoid arthritis and, 91
vascular, 69, 125
Depression, 28, 35–39
alcohol abuse and, 40
arthritis and, 100, 105
cancer and, 141, 144, 146
cardiovascular disease and,
37–38, 128–29, 130–31, 133
case study of, 42–43
cholesterol levels and, 30
diabetes and, 37, 38, 56, 59,
60, 69–70, 72, 73, 74, 76, 81, 87
disease association with,
36–38
immune function and, 32
low back pain and, 36, 105
in nursing home residents, 35
quality of life and, 31
rheumatoid arthritis and, 101
Dermatological conditions, 91
Diabetes mellitus (DM), 19, 37, 38, 44, 56–89. See also Type 1 diabetes; Type 2 diabetes
air pollution and, 14
cardiovascular disease and, 57,
60–61, 62, 63, 64, 82–83, 86, 125, 126, 127
complications and risk factors,
57–70
Diabetes mellitus (DM), 
(Continued) 
coping with, 75 
costs of treating, 22–23, 59 
disability and quality of life, 
70–73 
epidemiology of, 1, 3–4 
family and social support and, 
75–77 
heart failure and, 26 
obesity and, 3, 30, 56, 65, 
72–73, 88 
patient education and, 83, 
86–89 
rheumatoid arthritis and, 91 
self-management of, 86–89 
stress and, 73–75 
stress management and, 80–81 
treatment and rehabilitation 
outcomes, 77–89 
Diabetes Quality of Life Scale, 74 
Diabetic retinopathy, 61, 87 
Dialysis, 16, 63–64, 65, 98 
Diastolic blood pressure, low, 129 
Diastolic heart failure, 128 
Diet and nutrition, 12, 13 
diabetes and, 3, 76–77, 78–79 
quality of life and, 29, 30 
rheumatoid arthritis and, 106–7 
Dietary Guidelines for Americans, 
U.S., 79 
Digit span, 49 
Dikol, 88 
Disability 
arthritis and, 99–100 
cancer and, 142–45 
cardiovascular disease and, 
129–31 
depression and, 37 
diabetes and, 70–73 
fibromyalgia and, 104 
low back pain and, 104–5 
osteoarthritis and, 101–2 
osteoporosis and, 102–3 
prevalence of, 2 
rheumatoid arthritis and, 
100–101 
Disc disease, degenerative, 97, 
105 
Disease modifying anti-rheumatic 
drugs (DMARDs), 107, 109 
Divorce, 74 
Dopaminergic system, 46, 51 
Driving reduction or 
cessation, 37 
Economic and Social Research 
Council (United Kingdom), 
29 
Education level 
arthritis patients and, 124 
cardiovascular disease patients 
and, 126, 130, 138 
diabetics and, 58, 65, 70, 72, 87 
rheumatoid arthritis patients 
and, 100 
Elderly Diabetes Impact Scale, 75 
ELDER project. See Evaluating 
Long-term Diabetes Self-
management among Elder 
Rural Adults 
Electroencephalogram (EEG) 
coherence, 52 
ELVIS investigation, 144 
Emphysema, 1 
Enbrel (etanercept), 107 
Endocrine therapy, 148 
Endoscoping stenting, 150 
End-stage renal disease (ESRD), 
62, 63, 72 
Environmental hazards, 14 
EPESE. See Established 
Population for the 
Epidemiological Study of the 
Elderly 
EPIC. See European Prospective 
Investigation of Cancer 
Norfolk study
Epidemiology, 1–14
of arthritis, 1, 2, 4
of cancer, 1, 10–12
of cardiovascular disease, 1, 2, 4, 9–10
of diabetes mellitus, 1, 3–4
of fibromyalgia, 7–8
of low back pain, 8–9
of osteoarthritis, 5
of osteoporosis, 5–7
of rheumatoid arthritis, 5
Episodic memory, 46, 48, 50
Erectile dysfunction, 56, 65–66
Erythrocyte sedimentation rate values, 92
Esophageal cancer, 13
Established Population for the Epidemiological Study of the Elderly (EPESE), 57, 60, 62, 65, 70
Estrogen replacement therapy, 115
Etanercept (Enbrel), 107
Ethnicity. See Race and ethnicity
Etidronate, 121
European Prospective Investigation of Cancer (EPIC) Norfolk study, 106–7
Euthanasia, 38
Evaluating Long-term Diabetes Self-management among Elder Rural Adults (ELDER), 70
Event-based tasks, 50
Event-specific vicarious control techniques, 132
Executive function, 54
Exercise, 13, 29, 31. See also Inactivity
aerobic, 31, 79, 80, 86, 119
diabetes and, 73, 76, 79–80, 86
fibromyalgia and, 117, 118
low back pain and, 119
osteoarthritis and, 123
osteoporosis and, 112, 114
resistance, 79, 80, 86, 112, 137
Expiration dates, on medicine, 20
Explicit memory encoding, 53
Eye/vision problems
diabetes and, 57, 61, 72, 83, 87
epidemiology of, 2
treatment of, 83
Face recognition, 51
Falls. See also Fractures
alcohol use and, 40
arthritis and, 90
diabetes and, 56, 66
fibromyalgia and, 104
osteoporosis and, 103, 112
False memories, 48–49
Family support, 75–77. See also Social support
Fasting glucose levels, 61, 79
Fats, dietary, 78
Fee-for-service (FFS) plans, 16–17
Fiber, dietary, 79
Fibromyalgia (FM), 39
complications and risk factors, 95–96
costs of treating, 24, 25
disability and quality of life, 104
epidemiology of, 7–8
patient education and, 117, 119
self-management of, 123
treatment and rehabilitation outcomes, 117–19
First National Health Survey (Germany), 92
Fluid intelligence, 44–45, 46, 49
Fluorouracil, 150–51
Food and Drug Administration (FDA), 108, 117
Foot care, for diabetics, 83–85, 86
Foot ulcers, 61, 84
Forgiveness, quality of life and, 32–33
Fracture Prevention Trial, 103
Fractures
  diabetes and, 66–67
  fibromyalgia and, 104
  hip, 6, 24, 103
  low back pain and, 97, 98, 105
  osteoporosis and, 94–95, 97, 98, 121
  annual rate of, 5–6
  prevention of, 112, 113, 114–17
  rheumatoid arthritis and, 100
  vertebral (see Vertebral fractures)
Free recall tests, 48
Fremantle Diabetes Study, 71, 73
Freud, Sigmund, 40
Frontotemporal dementia, 53
Frontotemporal lobe, 52
Fruit consumption, 13, 106
Fusiform regions, 53
Gangrene, 64
Gemcitabine, 152, 153
Gender. See Men; Women
Geriatric syndromes, 86
Glucose intolerance, 30
Glucose levels, 56
  cognitive function and, 68
  fasting, 61, 79
  self-management of, 86–87
Glycemic control, 57, 77–78, 86
Gray matter, 52
Gross proteinuria, 62–63
HbA1c levels, 57, 60, 82
Health, Aging and Body Composition (HABC) study, 13, 57, 125
Health Assessment Questionnaire-Disability Index, 107, 109
Health care costs, 21–27
  for arthritis, 23
  for cancer, 26–27
  for cardiovascular disease, 25–26, 139
  case management services and, 15–16
  for diabetes, 22–23, 59
  for fibromyalgia, 24
  for low back pain, 24–25
  for osteoporosis, 24
  for rheumatoid arthritis, 23, 107
Health care rationing, 16
Health care utilization, 15–21
Health maintenance organizations (HMOs), 16, 17, 18
Health-related quality of life (HRQL), 21. See also Quality of life
Hearing aid use, 52
Hearing loss, 2
Heart attacks, 126. See also
  Myocardial infarction
  air pollution and, 14
  depression and, 36
  diabetes and, 60
  screening impact on, 26
  silent, 127
Heart disease, 28
  Alzheimer’s disease and, 69
  cost of, 25
  diet and, 13
  epidemiology of, 1, 9
  ischemic, 13, 37, 60, 131, 133
Heart failure (HF), 10, 125. See also
  Congestive heart failure
  Cognitive impairment and, 129
  coping with, 133
  cost of treating, 26
  diastolic, 128
  disability and quality of life, 131
  patient education and self-management, 137–38, 139, 140
  treatment and rehabilitation outcomes, 134, 135
Heart Failure Effectiveness & Leadership Team (HEARTFELT), 140
Heart Manual, 138–39
Hemoglobin A1c test, 84
Hepatitis C, 96
Herbal medicines, 19
Hip abduction movement, reduced, 93
Hip fractures, 6, 24, 103
Hippocampus, 48, 52, 53, 69
Hispanics. See also Mexican-Americans, diabetes in arthritis in, 4, 124
breast cancer in, 156
cancer in, 11, 12
diabetes in, 4, 58, 68, 76
epidemiology of disease in, 2
mammography for, 160
osteoporosis in, 5
Hormone replacement therapy, 115, 122
Hospitalization
average length of stay, 15
for cardiovascular disease, 26, 134–35
for diabetes, 22, 59–60
Hostility, impact on health, 31
Humira (adalimumab), 108
Hyalgan, 111
Hyaluronan, 111
Hyperglycemia, 58–59, 67, 80, 82, 86
Hyperlipidemia, 93, 126
Hyperosmolar hyperglycemic syndrome, 67
Hypertension, 10, 19, 28, 126, 127, 134
Alzheimer’s disease and, 69
cognitive impairment and, 44
cost of, 26
diabetes and, 56, 70, 78, 82, 83
disability and quality of life, 130
epidemiology of, 1, 2
osteoarthritis and, 93
rheumatoid arthritis and, 91
stress and, 14
systolic, 125
Hyperthyroidism, 94
Hypertriglyceridemia, 60
Hypoglycemia, 59–60, 63, 80, 82, 86
Hypotension, neurally-mediated, 119
Ibandronate, 114
Ibuprofen, 110
Immune function, 32, 107
Impulsiveness, mortality rates and, 41
Inactivity, 12. See also Exercise
diabetes and, 3, 73
osteoarthritis and, 101
osteoporosis and, 94
Incontinence, 56, 66
Infections
arthitis and, 4
fibromyalgia and, 96
low back pain and, 97, 98, 119
rheumatoid arthritis and, 91
Inflammatory arthritis (IA), 93–94, 101
Inflammatory polyarthritis, 106–7
Inflammatory spondylarthropathy, 94
Infliximab (Remicade), 107, 108
Influenza, 1
Insomnia, 39, 40, 96. See also Sleep disorders
Instrumental activities of daily living (IADLs), 2, 71, 154–55
Insulin, 56, 82, 86
disability related to, 71
eye disease and, 61
lower extremity disease and, 65
stress and, 74
Insulin resistance  
cardiovascular disease and, 60  
exercise and, 80  
metabolic syndrome and, 125  
obesity and, 73  
TNF blockers and, 107–8  
Insulin secretory reserve, 67  
Insulin sensitivity, 67  
Interactive Voice Response (IVR)-based systems, 89  
Interleukin-6, 13  
Internet, 155–56  
Intravenous drug abuse, 98  
Iowa Prostate Cancer Consensus Committee, 153–54  

drug and, 119  

disease, 119  

dysfunction, 96, 119  

dysfunction, 28  

disease and, 60  

disease and, 125  

disease and, 57, 59, 62–64, 85  

disease and, 62, 63, 72  

disease and, 85  

disease and, 93  

disease and, 91  
Kidney failure, 109  
Kidney transplants, 63  
Killip class of cardiac function, 126  
Kyphoplasty, 115–16  

Laminectomy, 119  
Laparoscopic-assisted colectomy (LAC), 150  
Lasofoxifene, 115  
Learning, age-related changes in, 50–52  
Leflunomide, 107  
Left ejection fraction, 131  
Leucopenia, 91  
Life expectancy, 1  
Lifestyle and behavioral factors, 12–14, 27, 28  
Lipids, blood. See Hyperlipidemia  
Listening span, 49  
Liver cirrhosis, 95  
Liver disease/dysfunction, 59, 91  
Liver toxicity, 109  
Lobectomy, 152  
London Fibromyalgia Epidemiology Study, 7, 95  
Longitudinal Aging Study Amsterdam, 39, 50–51  
Low back pain (LBP) complications and risk factors, 96–99  

costs of treating, 24–25  

depression and, 36, 105  

disability and quality of life, 104–5  

epidemiology of, 8–9  

treatment and rehabilitation outcomes, 119–20  
Lower extremity disease (LED), 64–65, 70–71, 72  
Lumbar spinal stenosis, 97, 119  
Lumbar total disc arthroplasty, 120  
Lumpectomy, 146–47  
Lung cancer, 11, 12, 13  

disability and quality of life, 143, 144  

non-small-cell, 144, 152–53  

small-cell, 153  

treatment and rehabilitation outcomes, 151–53
Lung disease. See Pulmonary disease
Lymphedema, 158

Magnetic resonance imaging
(MRI) studies, 48, 52, 53
Mammography, 147, 160
Managed care (MC), 16–17
Marijuana use, 40
Marital status. See also
Widowhood
of cardiovascular disease
patients, 126, 130, 132–33
of diabetics, 70, 73, 74
Mastectomy, 147
McArthur Foundation Study of
Aging in America, 31
Meat, red, 107
Medial temporal lobe, 52
Medicaid recipients, 110, 130
Medical Outcomes Study, 17
Medicare + Choice program
(Part C), 16
Medicare recipients, 1, 2
  cardiovascular disease in, 128
diabetes in, 3, 23
eye examinations for, 83
health care costs for, 16, 21
health care utilization in, 16–17
heart failure in, 10
low back pain in, 25
mammography for, 147, 160
osteoporosis in, 122
special footwear coverage
for, 84
Medications, 17–21
  for cardiovascular disease, 26
cognitive function and, 54
  complementary and alternative,
  19, 25, 155
cost of, 19, 21–22
  for diabetes, 19, 59, 81–82
  guidelines for improved utilization of, 20–21
  inappropriate use of, 17–20
  for osteoarthritis, 121
  for osteoporosis, 121–22
  over-the-counter, 17, 18–19, 25
Meditation, 14
Melanoma, 155–56
Memory
  age-related changes in, 47–50
  Alzheimer’s disease and, 53
depression and, 36
diabetes and, 68–69, 72
episodic, 46, 48, 50
explicit, 53
false, 48–49
information retrieval and,
  47–48
  prospective, 50
  secondary, 47
  short-term, 36, 49
  working, 46, 49
Men
  alcohol use in, 40
  arthritis in, 124
cancer in, 11
cardiovascular disease in, 126,
  127, 129, 132, 138
cardiovascular screening
  for, 26
depression in, 36, 37, 38
diabetes in, 3, 58, 65
epidemiology of disease in, 1
fibromyalgia in, 7
inappropriate medication use
  in, 18
inflammatory spondylarthropathy in, 94
low back pain in, 8, 99
osteoarthritis in, 93, 101, 102
osteoarthritis in, 6, 94,
  95, 103
rheumatoid arthritis in, 91,
  92, 101
Type A personality in, 31
vertebral deformity in, 6–7
Mental illness. See also specific disorders
arthritis and, 90
impact on the aging population, 35–43
treatment outcomes, 17
Mesial temporal lobe, 53
Metabolic syndrome, 78, 125–26
Methotrexate, 107, 108, 109
Mexican-Americans, diabetes in, 57–58, 60–61, 62, 65
depression and, 70
disability and, 71, 72
family and social support for, 76
joint/bone problems and, 66–67
patient education for, 86–87
Microalbuminuria, 62–63
MILES investigation, 144
Mini-Mental State Examination, 68
Mortality rates
from acute myocardial infarction, 126–27
atrial fibrillation and, 128
from cancer, 10–11
from cardiovascular disease, 9
from colorectal cancer surgery, 148–49
depression and, 37, 70
from diabetes, 57–59, 63, 64, 70
from kidney disease, 63, 64
leading causes of, 1
neuroticism and, 31
personality and, 41
rheumatoid arthritis and, 92
stress and, 14
from vertebral fractures, 6
Multiple sclerosis (MS), 36, 37, 39, 43
Multiple sensitivities, 119
Myocardial infarction (MI), 10.
See also Acute myocardial infarction; Heart attacks coping with, 132
diabetes and, 65, 70
metabolic syndrome and, 125
osteoarthritis and, 93
rehabilitation following, 136–37
Name recall, 51
National Ambulatory Medical Care Survey, 18
National Cancer Institute Information Service, 155
National Co-morbidity Survey Replication, 90
National Data Bank for Rheumatic Diseases, 100
National Fibromyalgia Association, 7
National Health and Nutrition Examination Survey (NHANES), 64, 72
National Health Interview Survey, 8, 124, 130
National Health Interview Survey Disability Supplement Phase Two, 99–100
National Registry of Atrial Fibrillation, 95
Native Americans, 4, 11, 70
Naturalistic prospective studies, 50
Neck pain, 9
Nephropathy, diabetic, 62, 64, 85
Neurally-mediated hypotension, 119
Neuropathy, diabetic, 56, 64, 84
Neuroticism, 31, 39
New York City Community Health Survey, 73–74
New York Hospital Association, 134
NHANES. See National Health and Nutrition Examination Survey
Nitroglycerin, 137
Nocturia, 62
Non-proliferative diabetic retinopathy, 61
Non-selective beta-adrenoceptor antagonists, 59
Non-small-cell lung cancer, 144, 152–53
Non-steroidal anti-inflammatory drugs (NSAIDs), 17, 107, 110
Nursing home care, 17, 21, 22, 35, 60
Nutrition. See Diet and nutrition

Obesity and overweight, 13. See also Body mass index
arthritis and, 4, 30, 99
diabetes and, 3, 30, 56, 65, 72–73, 88
health care costs and, 27
metabolic syndrome and, 125
osteoarthritis and, 93, 101
quality of life and, 29, 30
Occupation, 4, 92
Occupational therapy, 111–12
Operation span, 49
Opioids, 20, 110
Optimism, 31–32
Organ transplants, 16, 63
Osteoarthritis (OA)
complications and risk factors, 92–93
disability and quality of life, 101–2
epidemiology of, 5
low back pain and, 99, 105
patient education and self-management, 121, 122–23
treatment and rehabilitation outcomes, 109–12
Osteopenia, 114
Osteoporosis (OP), 28
complications and risk factors, 94–95
costs of treating, 24
disability and quality of life, 102–3
epidemiology of, 5–7
low back pain and, 97, 98, 105
osteoarthritis and, 93
patient education and self-management, 121–22
treatment and rehabilitation outcomes, 112–17
Osteoporosis Assessment Questionnaire, 103
Over-the-counter (OTC) medications, 17, 18–19, 25
Oxaliplatin, 151
Ozone, 14
Pacemakers, 130
Pacific Islanders, 4, 11

Pain
anxiety and, 39
cancer and, 142, 144, 145
diabetes and, 56, 67
fibromyalgia and, 104, 118
osteoarthritis and, 116
rheumatoid arthritis and, 101
suicide and, 38–39
Pancreatic beta cells, 56
Parathyroid hormone (PTH), 113, 115
Parkinson’s disease, 36, 37, 53
Particulate matter (PM), 14
Patient education
for arthritis patients, 124
for cancer patients, 155–60
for cardiovascular disease patients, 137–40
for diabetics, 83, 86–89
for fibromyalgia patients, 117, 119
for osteoarthritis patients, 121, 122–23
for osteoporosis patients, 121–22
<table>
<thead>
<tr>
<th>Subject Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient navigator services, 160</td>
</tr>
<tr>
<td>Peptic ulcer disease, 91, 93</td>
</tr>
<tr>
<td>Percutaneous electrical nerve stimulation (PENS), 120</td>
</tr>
<tr>
<td>Percutaneous transluminal coronary angioplasty, 130</td>
</tr>
<tr>
<td>Peripheral arterial disease (PAD), 64</td>
</tr>
<tr>
<td>Peripheral insensate neuropathy, 64</td>
</tr>
<tr>
<td>Peripheral neuropathy, 56, 84</td>
</tr>
<tr>
<td>Peripheral vascular disease, 91, 134</td>
</tr>
<tr>
<td>Personality, 31, 40–41</td>
</tr>
<tr>
<td>PFI-10, 73</td>
</tr>
<tr>
<td>Physical therapy, 116, 118, 119</td>
</tr>
<tr>
<td>Plaques (coronary artery), 26</td>
</tr>
<tr>
<td>Plasminogen activator inhibitor-1, 13</td>
</tr>
<tr>
<td>Platinum-based therapies, 152</td>
</tr>
<tr>
<td>Pneumonia, 1</td>
</tr>
<tr>
<td>Polymyalgia rheumatism, 94</td>
</tr>
<tr>
<td>Polypharmacy, 20</td>
</tr>
<tr>
<td>Positron emission tomography (PET), 48, 52</td>
</tr>
<tr>
<td>Post Traumatic Stress Disorder (PTSD), 144</td>
</tr>
<tr>
<td>Preferred Provider Organizations (PPOs), 16</td>
</tr>
<tr>
<td>Prefrontal cortex, 48, 49, 51, 52</td>
</tr>
<tr>
<td>Pregabalin, 117–18</td>
</tr>
<tr>
<td>Premature death, 14, 56</td>
</tr>
<tr>
<td>Prevalence</td>
</tr>
<tr>
<td>of arthritis, 4</td>
</tr>
<tr>
<td>of cancer, 11–12</td>
</tr>
<tr>
<td>of cardiovascular disease, 9</td>
</tr>
<tr>
<td>of diabetes, 2, 3–4</td>
</tr>
<tr>
<td>of fibromyalgia, 7</td>
</tr>
<tr>
<td>of hypertension, 2</td>
</tr>
<tr>
<td>of low back pain, 8–9</td>
</tr>
<tr>
<td>of osteoarthritis, 5</td>
</tr>
<tr>
<td>of osteoporosis, 5</td>
</tr>
<tr>
<td>Priming tests, 53</td>
</tr>
<tr>
<td>Problem Areas in Diabetes (PAID), 74</td>
</tr>
<tr>
<td>Processing speed, 44–47, 54</td>
</tr>
<tr>
<td>Progesterone replacement therapy, 115</td>
</tr>
<tr>
<td>Project LEAP, 84–85</td>
</tr>
<tr>
<td>Prospective memory, 50</td>
</tr>
<tr>
<td>Prostate cancer, 11</td>
</tr>
<tr>
<td>patient education and self-management, 159–60</td>
</tr>
<tr>
<td>treatment and rehabilitation outcomes, 153–55</td>
</tr>
<tr>
<td>Prostate disease, 28</td>
</tr>
<tr>
<td>Prostate-specific antigen (PSA), 154, 159</td>
</tr>
<tr>
<td>Proteinuria, 62–63</td>
</tr>
<tr>
<td>Psychological problems. See Mental illness</td>
</tr>
<tr>
<td>Psychosocial stress. See Stress</td>
</tr>
<tr>
<td>Puerto Ricans, 87</td>
</tr>
<tr>
<td>Pulmonary disease, 28, 93.</td>
</tr>
<tr>
<td>See also Respiratory disease</td>
</tr>
<tr>
<td>air pollution and, 14</td>
</tr>
<tr>
<td>cardiovascular disease and, 128–29</td>
</tr>
<tr>
<td>epidemiology of, 1</td>
</tr>
<tr>
<td>heart failure and, 26</td>
</tr>
<tr>
<td>rheumatoid arthritis and, 91, 92</td>
</tr>
<tr>
<td>Pulmonary resection, 152</td>
</tr>
<tr>
<td>Quality of life, 28–34</td>
</tr>
<tr>
<td>arthritis and, 99–100</td>
</tr>
<tr>
<td>cancer and, 142–45</td>
</tr>
<tr>
<td>cardiovascular disease and, 129–31</td>
</tr>
<tr>
<td>case studies of, 33–34</td>
</tr>
<tr>
<td>contributors to, 28</td>
</tr>
<tr>
<td>defined, 28</td>
</tr>
<tr>
<td>diabetes and, 70–73</td>
</tr>
<tr>
<td>diet/nutrition and, 29, 30</td>
</tr>
<tr>
<td>exercise and, 29, 31</td>
</tr>
<tr>
<td>fibromyalgia and, 104</td>
</tr>
<tr>
<td>low back pain and, 104–5</td>
</tr>
<tr>
<td>osteoarthritis and, 101–2</td>
</tr>
</tbody>
</table>
Quality of life, (Continued)
osteoporosis and, 102–3
productive activities and, 31
religion/spirituality and, 29,
32–33
rheumatoid arthritis and,
100–101
Questionnaire on Stress in
Patients with Diabetes
(revised) (QSD-R), 74

Race and ethnicity. See also
specific racial and ethnic
groups
cancer and, 11, 12, 146, 156,
157, 160
diabetes and, 4, 57–58, 61, 62,
65, 76, 87
epidemiology of disease by,
1–2
fibromyalgia and, 7
osteoporosis and, 5
Radiation therapy, 144
for breast cancer, 147, 157,
158–59
for colorectal cancer, 149
for lung cancer, 153
for prostate cancer, 154
Raloxifene, 114–15, 122
Raltitrexed, 151
Rancho Bernardo Study, 68
Rationing of health care, 16
Raynaud-like symptoms, 95, 96
Reaction time, changes in, 45–46,
47, 49
Reading span, 49
Rehabilitation facilities, 17
Religion and spirituality, 29,
32–33, 132
Remicade. See Infliximab
Renal disease/dysfunction. See
Kidney disease/
dysfunction
Reperfusion therapy, 126, 127
Report of the National
Cholesterol Education
Program, 78
Resistance exercise, 79, 80, 86,
112, 137
Respiratory disease, 1, 91. See
also Pulmonary disease
Response bias, 52
Restless leg syndrome, 119
Retinopathy, diabetic, 61, 87
Revascularization, 26, 135
Reward association learning, 51
Rheumatoid arthritis (RA)
complications and risk factors,
90–92
costs of treating, 23, 107
disability and quality of life,
100–101
epidemiology of, 5
treatment and rehabilitation
outcomes, 106–9
Rheumatoid arthritis (RA)
vasculitis, 92
Risedronate, 114, 121, 122
Risk factors
for arthritis, 90
for cancer, 141–42
for diabetes, 57–70
for fibromyalgia, 95–96
for inflammatory arthritis,
93–94
for low back pain, 96–99
for osteoarthritis, 92–93
for osteoporosis, 94–95
for rheumatoid arthritis,
90–92
Rituximab, 109
Rochester Epidemiology
Project, 93
Rural areas, 4, 70
St. Louis Mental Status
Examination (SLUMD), 68
Sciatica, 97–98
Screening for Heart Attack Prevention and Education (SHAPE) Task Force, 26
Secondary memory, 47
Sedentary lifestyle. See Inactivity
Selective lymph sentinel node technique, 147
Self-esteem, 144
Self-management for arthritis patients, 124
for cancer patients, 155–60
for cardiovascular disease patients, 137–40
for diabetics, 86–89
for fibromyalgia patients, 123
for osteoarthritis patients, 121, 122–23
for osteoporosis patients, 121–22
Septic arthritis, 101
Serial response time tasks, 51
Serotonergic system, 51
SHAPE Task Force. See Screening for Heart Attack Prevention and Education Task Force
Short-Form-36 Health Survey (SF-36), 73, 109
Short-term memory, 36, 49
Sicca-like symptoms, 96
Signaling effects, 50
Silent heart attacks, 127
Silent ischemia, 60
Skin cancer, 11
Sleep disorders, 35
alcohol use and, 40
anxiety and, 39
arthritis and, 100
depression and, 36
diabetes and, 72
fibromyalgia and, 96, 118, 119
Small-cell lung cancer, 153
Smoking, 12, 29, 31
Alzheimer’s disease and, 69
cardiovascular disease and, 138
diabetes and, 64, 65, 79
health care costs and, 27
osteoporosis and, 113, 114
rheumatoid arthritis and, 91
Social support, 29
for arthritis patients, 106
for cancer patients, 145–46
for cardiovascular disease patients, 131–33
for diabetics, 75–77
Socioeconomic status (SES), 12
of arthritis patients, 4
of cancer patients, 141
of cardiovascular disease patients, 126, 132
depression and, 37
of diabetics, 57–58, 72, 87
quality of life and, 29
Sodium restriction, 78, 138
Southern India, diabetic retinopathy in, 61
Speech comprehension, 52
Spinal stenosis, 105
Statins, 54
ST elevation myocardial infarction (STEMI), 126–27
Steroids, 91, 94, 110, 120
Stiffening disease, 125
Stomach cancer, 13
Strategy utilization, 49, 50
Stress, 13–14
arthritis and, 105
cancer and, 145–46
cardiovascular disease and, 131–33
case studies of response to, 41–43
diabetes and, 73–75
vulnerability to, 32
Stress incontinence, 66
Stress management, 80–81
Stroke, 10, 28, 125  
air pollution and, 14  
cognitive impairment and, 53  
cost of, 25  
diabetes and, 56, 60, 65, 72  
diet and, 13  
epidemiology of, 1, 2, 9  
ischemic, 13  
managed care for patients, 16–17  
mini, 41  
Strontium ranelate, 114, 115  
Sub-cortical vascular disease, 54  
Substance abuse, 35  
Sudden cardiac death, 31, 92  
Suicide/suicidal ideation, 36, 38–39, 43  
Sulfonylurea/sulphonylurea, 59, 82  
Sunlight exposure, 113  
Surgery  
for breast cancer, 146–47, 148, 157  
for colorectal cancer, 148–50  
increased utilization of, 21  
for low back pain, 119–20  
for lung cancer, 151–52  
for osteoarthritis, 111  
for osteoporosis, 115–16  
Systolic hypertension, 125  
Thoractomy, 152  
Thrombolysis, 130  
Thyroid autoimmunity, 96  
Thyroid disorders, 93  
Thyroid hormone, 54  
Time-based tasks, 50  
Time-dependent stimulus features, 51–52  
TNF. See Tumor necrosis factor  
Total mesorectal excision (TME), 149–50  
Trail-Making Test, 68  
Transanal endoscopic microsurgery (TEMS), 150  
Transcendental Meditation (TM), 14  
Transient ischemic attacks, 65  
Treatment and rehabilitation outcomes  
for cancer, 146–55  
for cardiovascular disease, 82–83, 133–37  
for diabetes, 77–89  
for eye/vision problems, 83  
for fibromyalgia, 117–19  
for low back pain, 119–20  
for mental illness, 17  
for osteoarthritis, 109–12  
for osteoporosis, 112–17  
for rheumatoid arthritis, 106–9  
Treatment of Peripheral Osteoporosis study, 115  
Tricyclic antidepressants, 117, 118–19  
Trigger point injections, 118  
Triglycerides, 125  
Tumor necrosis factor-alpha, 13  
Tumor necrosis factor (TNF) blockers, 107–9  
Twin studies, of low back pain, 8–9  
Type A personality, 31  
Type 1 diabetes, 38, 63, 64, 79
Type 2 diabetes, 76, 78, 79, 88
cognitive function and, 69
depression and, 38
disability and, 72–73
kidney dysfunction and, 62, 63, 64
lower extremity disease and, 65
osteoarthritis and, 93
stress and, 74
Type II Diabetes Patient Outcomes Research Team, 72–73
United States Renal Data System, 63
Upper cervical spine pathology, 91
Urge incontinence, 66
Urinary incontinence, 56, 66
Urinary tract infections, 62, 98
Varus thrust, 93
Varus-valgus alignment, 93
Vascular calcification, 125
Vascular dementia, 69, 125
Vegetable consumption, 13, 106
Verbal Fluency Test, 68
Vertebral deformity, 6–7
Vertebral fractures
  low back pain and, 98
  osteoporosis and, 6, 94, 95, 102–3, 114–16
  rheumatoid arthritis and, 100
Vertebroplasty, 115, 120
Veterans Affairs Medical Center, 84, 85
Veterans Affairs Normative Aging Study, 40
Video-assisted thoracoscopic resection (VATS), 152
Vinorelbine, 152, 153
Vision problems. See Eye/vision problems
Vitamin C, 106, 107
Vitamin D, 94, 113, 116, 117
Vitamin K antagonists, 94
Warfarin, 94–95
Water exercises, 119
Wedge resections, 152
Wedge vertebral deformities, 6
Weight loss, 29, 78. See also
  Obesity and overweight
Well Elderly Study, 111–12
White House Conference on Aging, 35
White matter, 52
Whites
  arthritis in, 4
  breast cancer in, 156
  cancer in, 11
diabetes in, 4, 57, 68, 70, 76, 86–87
  epidemiology of disease in, 2
  metabolic syndrome and, 125
  osteoporosis in, 5
Widowhood, 32, 74, 76–77
Willpower, 88
Women
  alcohol use in, 40
  anxiety in, 39
  arthritis in, 124
  cancer in, 11, 12
  cardiovascular disease in,
    126–27, 129, 131, 132, 134, 138
  cardiovascular screening for, 26
diabetes in, 3, 58, 70
  epidemiology of disease in, 1
  fibromyalgia in, 7
  hip fractures in, 6
  inappropriate medication use in, 18
  low back pain in, 8, 98, 99
  metabolic syndrome and, 125
  osteoarthritis in, 101, 102
Women (Continued)
osteoporosis in, 5, 6, 94, 95, 102–3, 112
Type A personality in, 31
vertebral deformity in, 6–7
Women Take PRIDE program, 139

Word recognition, automaticity of, 51
Working memory, 46, 49
Yoga, 137
Zeaxanthin, 106